10-Q: Acro Biomedical Reports Q3 2024: No Revenue, Mounting Deficit

Acro Biomedical Co., Ltd. reported no revenue for the third quarter and first nine months of 2024, with a growing accumulated deficit and significant going concern doubts.

Summary

• Reported no revenue for the three and nine months ended September 30, 2024, continuing a trend of no sales since December 31, 2022.
• Net loss for the three months ended September 30, 2024, was $(10,229), a significant reduction from $(1,589,490) in the same period of 2023, primarily due to the expiration of consultant contracts and full amortization of stock-based compensation.
• Net loss for the nine months ended September 30, 2024, was $(31,624), down from $(8,789,333) in the prior year's nine-month period.
• Cash balance as of September 30, 2024, was minimal at $701, a slight increase from $376 at December 31, 2023.
• Total liabilities increased to $324,180 as of September 30, 2024, from $315,473 at December 31, 2023.
• Accumulated deficit worsened to $(32,647,122) as of September 30, 2024, from $(32,615,498) at December 31, 2023.
• The company continues to rely on advances from a minority stockholder and an officer for funding, with $115,298 owed to related parties as of September 30, 2024.
• Research and development efforts for a cordyceps-infused chicken feed product did not yield a marketable product, and consultant contracts expired in May and August 2023.
• The company's common stock is traded on the OTC Market Group's Expert Market, which restricts public viewing of quotes and limits broker-dealer activity, making fundraising challenging.

Sentiment

Score: 1

Explanation: The company faces severe financial distress with no revenue, a growing deficit, and significant going concern doubts. Operational failures, ineffective controls, and limited market access for its stock paint a dire picture. The delayed filing further exacerbates negative sentiment.

Positives

• Reduced net loss for the three and nine months ended September 30, 2024, compared to the prior year, primarily due to the cessation of significant R&D and SG&A expenses related to consultant contracts.
• Slight increase in cash balance to $701 as of September 30, 2024, from $376 at December 31, 2023, indicating that financing activities covered operating cash burn.

Negatives

• No revenue generated for the three and nine months ended September 30, 2024, extending the period of no sales since December 31, 2022.
• Accumulated deficit increased to $(32,647,122) as of September 30, 2024.
• Total current assets are extremely low at $701, while total current liabilities are $317,304, resulting in a significant working capital deficiency of $(316,603).
• Net cash used in operating activities increased to $(26,177) for the nine months ended September 30, 2024, compared to $(2,833) in the prior year, despite lower net loss, indicating continued operational cash burn.
• Research and development efforts for a cordyceps-infused chicken feed product failed to produce a marketable product, and consultant contracts have expired.
• The company's common stock is on the OTC Market Group's Expert Market, severely limiting liquidity and making it difficult to raise capital through equity financing.
• The company is delinquent in its filings with the Securities and Exchange Commission.
• Significant reliance on non-interest-bearing advances from a minority stockholder and an officer for funding, with no assurance of continued support.
• Disclosure controls were deemed ineffective as of September 30, 2024, due to inadequate internal controls, lack of segregation of duties, and reliance on a single part-time CEO/CFO.
• The company has no full-time employees, and its CEO/CFO works part-time without compensation, raising concerns about operational capacity and governance.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to minimal cash, no revenue, operating losses, and negative cash flow.
• Inability to raise necessary financing through debt or equity securities, exacerbated by the common stock being on the OTC Expert Market and delinquent SEC filings.
• Inability to increase customer base and supply chain.
• Inability to increase gross margins.
• Difficulty in hiring and retaining qualified research and development, marketing, and administrative personnel, especially given the reliance on equity-based compensation for a stock with limited marketability.
• Failure to develop marketable products or generate revenue and profits in the future.
• Impact of political instability in Hong Kong on sales, as past customers were Hong Kong-based and sold into the PRC.
• Adverse effects of inflation, supply chain disruptions, and increased tariffs on costs and ability to pass on price increases.
• Lingering aftereffects of COVID-19 restrictions and China's Zero COVID policy on customer demand and ability to pay, as evidenced by the $480,000 accounts receivable reserve in 2023.
• Material weaknesses in internal controls over financial reporting, including absence of segregation of duties, lack of qualified accounting personnel, and excessive reliance on third-party consultants.

Future Outlook

The company anticipates continued operational challenges, including the inability to generate revenue, develop marketable products, or secure external financing. It expects to incur marketing and other expenses without assurance of significant revenue or cash flow. The company cannot assure continued funding from its minority stockholder and may rely on equity-based compensation, which is challenging given its stock's Expert Market status.

Management Comments

• "We cannot assure you that we can or will develop any products or generate revenue or profits in the future."
• "We do not have the funds or the revenue stream for us to hire any consultants or employees."
• "Because of our financial condition, the lack of sales subsequent to December 31, 2022, along with the absence of an active market for our stock and our stock being traded on the OTC Market Groups Expert Market... it may be difficult for us to raise funds in the equity market, and, if we are able to raise funds our stockholders may suffer significant dilution."
• "Our primary source of funds for the years ended December 31, 2023 and 2022 and the nine months ended September 30, 2024 has been advances from a minority stockholder. This stockholder has continued to be our principal source of funds. We cannot assure you that he will continue to provide funding for us."
• "Our inability to generate sales partially resulted from the aftereffects of the COVID-19 restrictions of the Chinese government."
• "Our disclosure controls were not effective as of September 30, 2024, such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SECs rules and forms and (ii) accumulated and communicated to the president and treasurer, as appropriate to allow timely decisions regarding disclosure."
• "The lack of any separation of duties, with the same person, who is our only employee who serves as both chief executive officer and chief financial officer, who is our sole director and who does not have an accounting background and serves on a part-time basis, makes it unlikely that we will be able to implement effective internal controls over financial reporting in the near future."

Industry Context

Acro Biomedical operates in the niche market of cordyceps-related nutritional products, a segment often associated with traditional Chinese medicine. The company's challenges, including lack of sales and failed R&D, highlight the difficulties smaller players face in developing and commercializing products, especially when reliant on volatile international markets like China, which was impacted by COVID-19 policies. The company's inability to generate revenue or develop new products contrasts sharply with successful, well-funded companies in the broader health and wellness or biotech sectors that consistently invest in R&D and market expansion.

Comparison to Industry Standards

• The company's complete lack of revenue since December 31, 2022, and its failure to develop any marketable products from its R&D efforts, are significantly below industry standards for a publicly traded biomedical or nutritional products company.
• Companies like Herbalife Nutrition Ltd. or GNC Holdings Inc. (historically a public benchmark) in the nutritional supplement space typically report substantial, recurring revenues and invest in product innovation that leads to market entry. Acro Biomedical's situation is not comparable to any successful public company in this sector.
• The reliance on a single, unpaid, part-time CEO/CFO for all executive and financial functions, coupled with ineffective disclosure controls and material weaknesses in internal financial reporting, falls far short of corporate governance and operational standards expected of public companies, even small reporting companies.
• The company's stock being relegated to the OTC Expert Market, with no public quotes, indicates a severe lack of investor confidence and market access, unlike even micro-cap peers that maintain more liquid trading environments.

Corporate Governance

Related Party Transactions

• A minority stockholder advanced $1,000 and paid expenses of $25,502 on behalf of the company during the nine months ended September 30, 2024.
• As of September 30, 2024, the company owed $114,198 to this minority stockholder for non-interest-bearing advances and paid expenses, due on demand.
• As of September 30, 2024, the company owed $1,100 to its chief executive officer for non-interest-bearing advances and paid expenses, due on demand.
• The company imputed interest at 4% on these related party advances, totaling $3,134 for the nine months ended September 30, 2024.
• A minority stockholder paid the security deposit and monthly rent for a storage facility in Hong Kong, which the company leases.

Stakeholder Impact

• Shareholders: Face significant dilution risk if capital is raised, severe liquidity issues for their shares due to OTC Expert Market listing, and substantial doubt about the company's ability to continue as a going concern, likely leading to a complete loss of investment.
• Creditors (Related Parties): The minority stockholder and CEO are providing critical funding, but their advances are non-interest-bearing and due on demand, placing them at high risk given the company's financial instability.
• Employees: Currently, only the CEO works part-time without compensation, indicating no direct impact on a broader employee base, but also a lack of capacity. Future employees/consultants may be reluctant to accept equity compensation due to stock illiquidity.
• Customers: No current customers or orders, indicating no direct impact, but past customers faced payment difficulties due to economic conditions.
• Suppliers: No current inventory purchases, but past issues with purchase deposit write-offs suggest potential risks for future suppliers.

Next Steps

• Generate revenue from products (currently no orders).
• Seek to raise funds through equity financing arrangements or loan facilities.
• Increase customer base and supply chain.
• Increase gross margins.
• Hire and retain qualified research and development, marketing, and administrative personnel.
• Develop and market new products.
• Comply with government regulations related to product manufacture, distribution, and marketing.
• Address material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

Acro Biomedical Co., Ltd. presents an extremely high-risk investment profile. The company has generated no revenue since December 31, 2022, operates with minimal cash, and has a rapidly increasing accumulated deficit. Management explicitly states 'substantial doubt about our ability to continue as a going concern.' Furthermore, the company's stock trades on the OTC Expert Market, severely limiting liquidity and making it nearly impossible for investors to sell shares. Significant corporate governance issues, including ineffective disclosure controls and material weaknesses in internal financial reporting, coupled with a sole, unpaid, part-time CEO/CFO, indicate a profound lack of operational and financial oversight. The delayed filing of this 10-Q further underscores these systemic problems. Given the complete absence of a viable business model, severe financial distress, and lack of market access for its shares, a seasoned investor would strongly recommend selling any existing holdings or avoiding investment entirely.

Keywords

Acro Biomedical, cordyceps, nutritional products, SEC filing, 10-Q, going concern, OTC Expert Market, financial deficit, related party financing, biomedical, traditional Chinese medicine, corporate governance, internal controls, research and development failure